Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats
- PMID: 31862556
- PMCID: PMC6981050
- DOI: 10.1016/j.drugalcdep.2019.107804
Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats
Abstract
Background: Individuals with opioid use disorder (OUD) exhibit high levels of economic demand for opioids, with high levels of consumption and relative insensitivity to changes in price. Because the medications used to treat OUD in medication-assisted therapy (MAT) act as antagonists or agonists at μ opioid receptors, they may alter the relationship between price and opioid intake.
Methods: This study examined demand for a commonly abused synthetic prescription opioid, fentanyl, in male rats following s.c. pre-treatment with naltrexone (0.1-1.0 mg/kg), morphine (0.3-3.0 mg/kg) or buprenorphine (0.3-3.0 mg/kg). We normalized demand curves to intake at the lowest price and estimated effects on elasticity (sensitivity to changes in price). Rats were first trained to earn fentanyl (5 μg/kg/infusion) on a fixed ratio schedule, then they underwent daily training under a threshold procedure designed to produce within-session demand curve estimates. Rats received 14 threshold sessions before undergoing a series of tests encompassing each drug, at each dose.
Results: Elasticity was increased by pretreatment with naltrexone, morphine or buprenorphine. Morphine also decreased initial intake, when the price for fentanyl was lowest. In contrast, initial intake was increased by naltrexone (according to an inverted-U shaped curve). The effects of naltrexone did not persist after the test session, but morphine and buprenorphine continued affecting demand elasticity 24 h or 48 h after the test, respectively.
Conclusions: These results indicate that fentanyl demand is sensitive to blockade or activation of opioid receptors by the drug classes used for MAT in humans.
Keywords: Behavioral economics; Buprenorphine; Demand; Fentanyl; MAT; Morphine; Naltrexone.
Copyright © 2019 Elsevier B.V. All rights reserved.
Conflict of interest statement
5. Author disclosures
No conflicts to report.
Figures




Similar articles
-
The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.Psychopharmacology (Berl). 1998 Nov;140(1):20-8. doi: 10.1007/s002130050734. Psychopharmacology (Berl). 1998. PMID: 9862398
-
Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.J Pharmacol Exp Ther. 2002 Jul;302(1):101-10. doi: 10.1124/jpet.302.1.101. J Pharmacol Exp Ther. 2002. PMID: 12065706
-
In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.J Pharmacol Exp Ther. 1994 Nov;271(2):959-68. J Pharmacol Exp Ther. 1994. PMID: 7965818
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Adjunctive memantine for opioid use disorder treatment: A systematic review.J Subst Abuse Treat. 2019 Dec;107:38-43. doi: 10.1016/j.jsat.2019.10.003. Epub 2019 Oct 20. J Subst Abuse Treat. 2019. PMID: 31757263
Cited by
-
Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.Neuropsychopharmacology. 2022 Nov;47(12):2132-2139. doi: 10.1038/s41386-022-01393-3. Epub 2022 Jul 29. Neuropsychopharmacology. 2022. PMID: 35906489 Free PMC article.
-
Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.ACS Chem Neurosci. 2022 Dec 21;13(24):3608-3628. doi: 10.1021/acschemneuro.2c00526. Epub 2022 Nov 30. ACS Chem Neurosci. 2022. PMID: 36449691 Free PMC article.
-
Impacts of xylazine on fentanyl demand, body weight, and acute withdrawal in rats: A comparison to lofexidine.Neuropharmacology. 2024 Mar 1;245:109816. doi: 10.1016/j.neuropharm.2023.109816. Epub 2023 Dec 20. Neuropharmacology. 2024. PMID: 38128606 Free PMC article.
-
Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.Exp Clin Psychopharmacol. 2024 Apr;32(2):150-157. doi: 10.1037/pha0000670. Epub 2023 Jul 20. Exp Clin Psychopharmacol. 2024. PMID: 37470999 Free PMC article.
-
Effects of NMDA receptor antagonists on behavioral economic indices of cocaine self-administration.Drug Alcohol Depend. 2022 Apr 1;233:109348. doi: 10.1016/j.drugalcdep.2022.109348. Epub 2022 Feb 12. Drug Alcohol Depend. 2022. PMID: 35176632 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials